Sectoral Asset Management Inc lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 61.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 47,799 shares of the biopharmaceutical company’s stock after selling 75,800 shares during the period. Sectoral Asset Management Inc owned about 0.10% of Agios Pharmaceuticals worth $3,191,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. QS Investors LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $144,000. Cubist Systematic Strategies LLC boosted its holdings in Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the last quarter. Aperio Group LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $206,000. Teacher Retirement System of Texas acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth about $225,000. Finally, S&CO Inc. acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth about $227,000. Institutional investors and hedge funds own 94.38% of the company’s stock.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at $60.83 on Friday. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.63) earnings per share. equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price on the stock. SunTrust Banks set a $80.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, November 19th. Finally, Needham & Company LLC boosted their target price on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $75.70.

In other Agios Pharmaceuticals news, insider Scott Biller sold 15,000 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $65.00, for a total value of $975,000.00. Following the completion of the transaction, the insider now owns 6,264 shares in the company, valued at $407,160. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 6,000 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $61.55, for a total transaction of $369,300.00. Following the transaction, the chief executive officer now owns 6,000 shares of the company’s stock, valued at approximately $369,300. The disclosure for this sale can be found here. In the last three months, insiders sold 178,908 shares of company stock worth $12,157,364. 5.43% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/08/sectoral-asset-management-inc-sells-75800-shares-of-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.